
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1984274/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Supraclavicular versus infraclavicular approach for ultrasoundâ€guided right subclavian venous catheterisation: a randomised controlled nonâ€inferiority trial. Anaesthesia, 2022, 77, 59-65.	3.8	14
2	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2022, 20, 1343-1353.e16.	4.4	9
3	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2022, 76, 311-318.	3.7	48
4	Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 387-394.	2.8	10
5	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver International, 2022, 42, 320-329.	3.9	7
6	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology, 2022, 76, 492-501.	7.3	26
7	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study Journal of Clinical Oncology, 2022, 40, 433-433.	1.6	6
8	Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults. Journal of Clinical Medicine, 2022, 11, 935.	2.4	6
9	Platelet-to-White Blood Cell Ratio Is Associated with Adverse Outcomes in Cirrhotic Patients with Acute Deterioration. Journal of Clinical Medicine, 2022, 11, 2463.	2.4	5
10	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Diagnostics, 2022, 12, 1170.	2.6	7
11	Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. Cancers, 2022, 14, 2617.	3.7	4
12	Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clinical and Molecular Hepatology, 2022, 28, 425-472.	8.9	14
13	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. Clinical Gastroenterology and Hepatology, 2021, 19, 976-986.e5.	4.4	13
14	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	7.0	27
15	Association of Metabolic Risk Factors With Risks of Cancer and All ause Mortality in Patients With Chronic Hepatitis B. Hepatology, 2021, 73, 2266-2277.	7.3	45
16	Lung Shunt Reduction for Yttrium-90 Radioembolization: Chemoembolization <i>Versus</i> Radioembolization. In Vivo, 2021, 35, 2305-2312.	1.3	3
17	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. Korean Journal of Radiology, 2021, 22, 179.	3.4	8
18	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clinical and Molecular Hepatology, 2021, 27, 346-359.	8.9	10

#	Article	IF	CITATIONS
19	Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response. Anticancer Research, 2021, 41, 2625-2635.	1.1	2
20	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 587-598.	3.7	1
21	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. Gut and Liver, 2021, 15, 895-903.	2.9	3
22	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 613-623.	3.7	9
23	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. Journal of Viral Hepatitis, 2021, 28, 1392-1399.	2.0	13
24	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. Cancer Gene Therapy, 2021, , .	4.6	4
25	IDDF2021-ABS-0080â€96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
26	Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology, 2021, 74, 1737-1749.	7.3	27
27	Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis. Korean Journal of Radiology, 2021, 22, 1658.	3.4	10
28	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clinical and Translational Gastroenterology, 2021, 12, e00290.	2.5	9
29	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. Liver Cancer, 2021, 10, 72-81.	7.7	19
30	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. Korean Journal of Radiology, 2021, 22, 1974.	3.4	18
31	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 6009.	3.7	9
32	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1565-1577.	3.7	12
33	The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. Biomedicines, 2021, 9, 1948.	3.2	4
34	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. Journal of Clinical Gastroenterology, 2020, 54, 370-377.	2.2	0
35	Prognosis of surgical hernia repair in cirrhotic patients with refractory ascites. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2020, 24, 481-488.	2.0	3
36	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. Cancers, 2020, 12, 2791.	3.7	25

#	Article	IF	CITATIONS
37	P914 Changes of echocardiographic parameters in primary mitral regurgitation and determinants of symptom: an assessment from the Asian valve registry data. European Heart Journal Cardiovascular Imaging, 2020, 21, .	1.2	0
38	P1274 Early surgery versus watchful waiting in patients with moderate aortic stenosis and left ventricular systolic dysfunction. European Heart Journal Cardiovascular Imaging, 2020, 21, .	1.2	0
39	Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma. Anticancer Research, 2020, 40, 4191-4198.	1.1	7
40	Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. Cancers, 2020, 12, 1805.	3.7	23
41	Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). The Lancet Gastroenterology and Hepatology, 2020, 5, 839-849.	8.1	32
42	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. American Journal of Gastroenterology, 2020, 115, 1217-1225.	0.4	16
43	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. Digestive Diseases and Sciences, 2020, 66, 2427-2438.	2.3	3
44	Combination of 1 <sup>st</sup> and 2 <sup>nd</sup> Week Dosing of Glass Yttrium-90 Microspheres for Superselective Radioembolization. In Vivo, 2020, 34, 2763-2768.	1.3	4
45	A non-synonymous variant rs12614 of complement factor B associated with risk of chronic hepatitis B in a Korean population. BMC Medical Genetics, 2020, 21, 241.	2.1	0
46	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer, 2020, 20, 1001.	2.6	4
47	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut, 2020, 69, 2214-2222.	12.1	20
48	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis Bâ€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1960-1968.	2.8	13
49	P1368 Effect of angiotensin receptor blocker in patients with moderate or severe aortic stenosis: a randomized controlled trial. European Heart Journal Cardiovascular Imaging, 2020, 21, .	1.2	0
50	Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study. Drug Design, Development and Therapy, 2020, Volume 14, 1341-1349.	4.3	1
51	Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study Journal of Clinical Oncology, 2020, 38, e16680-e16680.	1.6	5
52	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. PLoS ONE, 2020, 15, e0239733.	2.5	8
53	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clinical and Molecular Hepatology, 2020, 26, 328-339.	8.9	32
54	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. Gut and Liver, 2020, 14, 225-231.	2.9	2

#	Article	IF	CITATIONS
55	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. Gut and Liver, 2020, 14, 477-485.	2.9	1
56	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. Gut and Liver, 2020, 14, 755-764.	2.9	17
57	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. Gut and Liver, 2020, 14, 377-386.	2.9	1
58	Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C. Gut and Liver, 2020, 14, 368-376.	2.9	3
59	Compositional differences in atherosclerosis between the major epicardial arteries; a secondary analysis from the PARADIGM study. European Heart Journal, 2020, 41, .	2.2	0
60	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986607.	3.2	21
61	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers, 2019, 11, 1721.	3.7	8
62	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers, 2019, 11, 1295.	3.7	11
63	Additional fibrate treatment in UDCAâ€refractory PBC patients. Liver International, 2019, 39, 1776-1785.	3.9	24
64	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Journal of Hepatology, 2019, 71, 35-44.	3.7	29
65	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 1292.	4.1	32
66	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. Journal of Hepatology, 2019, 70, 1093-1102.	3.7	107
67	Contact System Activation and Neutrophil Extracellular Trap Markers: Risk Factors for Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961882531.	1.7	36
68	A Model to Predict 1â€Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure. Hepatology, 2019, 70, 621-629.	7.3	23
69	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. European Radiology, 2019, 29, 3122-3131.	4.5	17
70	Hepatitis B virus X protein induces size-selective membrane permeabilization through interaction with cardiolipin. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 729-737.	2.6	9
71	Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly. Virus Research, 2019, 263, 102-111.	2.2	17
72	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Investigational New Drugs, 2019, 37, 567-572.	2.6	44

#	Article	IF	CITATIONS
73	Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. Journal of Hepatology, 2019, 70, 684-691.	3.7	136
74	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunology, Immunotherapy, 2019, 68, 23-32.	4.2	62
75	Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm. Journal of Vascular and Interventional Radiology, 2019, 30, 1-8.	0.5	26
76	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. Genes and Immunity, 2019, 20, 1-9.	4.1	13
77	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. Journal of Liver Cancer, 2019, 19, 128-135.	1.1	1
78	Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Digestive Diseases and Sciences, 2018, 63, 1062-1071.	2.3	23
79	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. European Radiology, 2018, 28, 3513-3521.	4.5	24
80	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 65-75.	7.7	23
81	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis Bâ€endemic area. Alimentary Pharmacology and Therapeutics, 2018, 47, 1490-1501.	3.7	22
82	Multiplatform Genomic Roadmap of Hepatocellular Carcinoma: A Matter of Molecular Heterogeneity. Hepatology, 2018, 68, 2029-2032.	7.3	14
83	A Model for Adaptive Decision Making of "Ablate-and-Wait―Versus Transplantation in Patients With Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2018, 52, 655-661.	2.2	1
84	Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2018, 50, 389-395.	0.9	18
85	Genetic association of complement component 2 variants with chronic hepatitis B in a Korean population. Liver International, 2018, 38, 1576-1582.	3.9	11
86	Entecavir and tenofovir reduce hepatitis B virusâ€related hepatocellular carcinoma recurrence more effectively than other antivirals. Journal of Viral Hepatitis, 2018, 25, 707-717.	2.0	23
87	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	2.6	18
88	Yttrium-90 Radioembolization of the Right Inferior Phrenic Artery in 20 Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, 556-563.	0.5	19
89	Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis, 2018, 272, 137-144.	0.8	38
90	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. Journal of Hepatology, 2018, 68, 431-440.	3.7	147

#	Article	IF	CITATIONS
91	A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization. Journal of Viral Hepatitis, 2018, 25, 412-420.	2.0	14
92	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in <scp>HB</scp> eAgâ€positive high viral load chronic hepatitis B. Journal of Viral Hepatitis, 2018, 25, 552-560.	2.0	11
93	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2018, 52, e18-e26.	2.2	13
94	Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio. Gut and Liver, 2018, 12, 714-721.	2.9	16
95	P2485Longitudinal quantitative assessment of coronary plaque progression related to glycemic status using serial coronary computed tomography angiography. European Heart Journal, 2018, 39, .	2.2	0
96	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. Gastroenterology Research and Practice, 2018, 2018, 1-9.	1.5	1
97	P2486Differential association between the progression of coronary artery calcium and coronary plaque volume progression according to statins. European Heart Journal, 2018, 39, .	2.2	0
98	Analysis of significant protein abundance from multiple reaction-monitoring data. BMC Systems Biology, 2018, 12, 123.	3.0	0
99	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. Journal of Korean Medical Science, 2018, 33, e283.	2.5	21
100	PI3KδIs a Therapeutic Target in Hepatocellular Carcinoma. Hepatology, 2018, 68, 2285-2300.	7.3	35
101	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Scientific Reports, 2018, 8, 13651.	3.3	7
102	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. International Journal of Molecular Medicine, 2018, 42, 2551-2559.	4.0	12
103	Transforming growth factorâ€Î² decreases side population cells in hepatocellular carcinoma inÃ⁻¿½vitro. Oncology Letters, 2018, 15, 8723-8728.	1.8	7
104	A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Annals of Surgical Treatment and Research, 2018, 94, 74.	1.0	56
105	Comparison of overall survival between antiviralâ€induced viral suppression and inactive phase chronic hepatitis B patients. Journal of Viral Hepatitis, 2018, 25, 1161-1171.	2.0	18
106	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. Journal of Medical Virology, 2018, 90, 1593-1603.	5.0	6
107	Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial. PLoS ONE, 2018, 13, e0192173.	2.5	14
108	Timing of upper gastrointestinal endoscopy does not influence short-term outcomes in patients with acute variceal bleeding. World Journal of Gastroenterology, 2018, 24, 5025-5033.	3.3	14

#	Article	IF	CITATIONS
109	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Research and Treatment, 2018, 50, 366-373.	3.0	15
110	Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. Gut and Liver, 2018, 12, 571-582.	2.9	6
111	Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding. Gut and Liver, 2018, 12, 704-713.	2.9	34
112	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. Journal of Proteome Research, 2017, 16, 1239-1248.	3.7	27
113	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. Cancer Biology and Therapy, 2017, 18, 67-75.	3.4	13
114	Perceived needs for the information communication technology (ICT)â€based personalized health management program, and its association with information provision, healthâ€related quality of life (HRQOL), and decisional conflict in cancer patients. Psycho-Oncology, 2017, 26, 1810-1817.	2.3	9
115	Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alphaâ€inhibitory dithiolethione in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1073-1083.	3.7	56
116	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology, 2017, 66, 855-868.	7.3	35
117	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology, 2017, 66, 1556-1569.	7.3	92
118	Letter: the efficacy of oltipraz in patients with nonâ€alcoholic fatty liver disease has not been confirmed—authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 210-210.	3.7	0
119	Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncolmmunology, 2017, 6, e1328335.	4.6	38
120	Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). Molecular and Cellular Proteomics, 2017, 16, 1312-1323.	3.8	25
121	Monotherapy with tenofovir disoproxil fumarate for multiple drugâ€resistant chronic hepatitis B: 3â€year trial. Hepatology, 2017, 66, 772-783.	7.3	37
122	Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. Journal of Vascular and Interventional Radiology, 2017, 28, 502-512.	0.5	34
123	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen–Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Journal of Infectious Diseases, 2017, 216, 1407-1414.	4.0	33
124	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nature Communications, 2017, 8, 839.	12.8	107
125	Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Alimentary Pharmacology and Therapeutics, 2017, 46, 845-855.	3.7	73
126	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. Digestive and Liver Disease, 2017, 49, 1273-1279.	0.9	5

#	Article	IF	CITATIONS
127	Prophylactic Temporary Occlusion of the Cystic Artery Using a Fibered Detachable Coil During 90Y Radioembolization. CardioVascular and Interventional Radiology, 2017, 40, 1624-1630.	2.0	13
128	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. European Radiology, 2017, 27, 1448-1458.	4.5	31
129	Identification of novel <i><scp>OCT</scp>4</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. Liver International, 2017, 37, 354-361.	3.9	13
130	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 347-354.	3.7	103
131	Thermal Injury–induced Hepatic Parenchymal Hypoperfusion: Risk of Hepatocellular Carcinoma Recurrence after Radiofrequency Ablation. Radiology, 2017, 282, 880-891.	7.3	16
132	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS ONE, 2017, 12, e0166188.	2.5	8
133	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS ONE, 2017, 12, e0170394.	2.5	11
134	3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLoS ONE, 2017, 12, e0174271.	2.5	18
135	Current status and strategies for viral hepatitis control in Korea. Clinical and Molecular Hepatology, 2017, 23, 189-195.	8.9	21
136	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naÃ <sup>-</sup> ve patients. Clinical and Molecular Hepatology, 2017, 23, 66-73.	8.9	13
137	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. Korean Journal of Radiology, 2017, 18, 799.	3.4	12
138	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. Korean Journal of Internal Medicine, 2017, 32, 261-268.	1.7	8
139	Current status and strategies for hepatitis B control in Korea. Clinical and Molecular Hepatology, 2017, 23, 205-211.	8.9	89
140	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget, 2017, 8, 47555-47564.	1.8	1
141	Acute Respiratory Failure Caused by Hepatopulmonary Fistula in a Patient with Hepatocellular Carcinoma. Tuberculosis and Respiratory Diseases, 2016, 79, 179.	1.8	4
142	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS ONE, 2016, 11, e0160822.	2.5	38
143	High titers of antiâ€HBs prevent rituximabâ€related viral reactivation in resolved hepatitis B patient with nonâ€Hodgkin's lymphoma. Journal of Medical Virology, 2016, 88, 1010-1017.	5.0	50
144	MicroRNA Profile of Granulosa Cells after Ovarian Stimulation Differs According to Maturity of Retrieved Oocytes. Geburtshilfe Und Frauenheilkunde, 2016, 76, 704-708.	1.8	11

#	Article	IF	CITATIONS
145	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naÃ <sup>-</sup> ve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology International, 2016, 10, 947-955.	4.2	17
146	A phase 3b study of sofosbuvir plus ribavirin in treatmentâ€naive and treatmentâ€experienced Korean patients chronically infected with genotype 2 hepatitis C virus. Journal of Viral Hepatitis, 2016, 23, 358-365.	2.0	28
147	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2016, 83, 607-616.	5.6	30
148	Autoimmune liver diseases in the Asia–Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatology International, 2016, 10, 909-915.	4.2	41
149	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. Journal of Bioenergetics and Biomembranes, 2016, 48, 581-590.	2.3	4
150	Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. British Journal of Radiology, 2016, 89, 20160383.	2.2	10
151	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. British Journal of Cancer, 2016, 115, 1201-1205.	6.4	19
152	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. Medicine (United States), 2016, 95, e4551.	1.0	13
153	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Annals of Surgery, 2016, 263, 842-850.	4.2	105
154	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 2568-2577.	2.3	22
155	17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochemical and Biophysical Research Communications, 2016, 473, 1247-1254.	2.1	24
156	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut, 2016, 65, 852-860.	12.1	70
157	Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clinical Cancer Research, 2016, 22, 1256-1264.	7.0	94
158	Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 132-138.e4.	4.4	117
159	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut, 2016, 65, 1042-1051.	12.1	76
160	Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS ONE, 2016, 11, e0154986.	2.5	48
161	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. PLoS ONE, 2016, 11, e0161980.	2.5	14
162	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS ONE, 2016, 11, e0165722.	2.5	33

#	Article	IF	CITATIONS
163	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. Clinical and Molecular Hepatology, 2016, 22, 286-291.	8.9	15
164	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (United States), 2015, 94, e2159.	1.0	85
165	Sorafenib inhibits cancer side population cells by targeting c-Jun N-terminal kinase signaling. Molecular Medicine Reports, 2015, 12, 8247-8252.	2.4	7
166	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. Molecular Medicine Reports, 2015, 11, 263-268.	2.4	4
167	Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. Journal of Medical Virology, 2015, 87, 999-1007.	5.0	Ο
168	Association of <i><scp>VARS</scp>2â€<scp>SFTA</scp>2</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. Liver International, 2015, 35, 1934-1940.	3.9	21
169	Forns index predicts recurrence and death in patients with hepatitis Bâ€related hepatocellular carcinoma after curative resection. Liver International, 2015, 35, 1992-2000.	3.9	15
170	Efficacy of antiviral prophylaxis in <scp>HB</scp> sAgâ€negative, antiâ€ <scp>HB</scp> c positive patients undergoing hematopoietic stem cell transplantation. Liver International, 2015, 35, 2530-2536.	3.9	24
171	The association between microRNAâ€323b polymorphism and hepatitis B virus persistent infection – some problems should be addressed. Journal of Viral Hepatitis, 2015, 22, 626-626.	2.0	Ο
172	The Korean guideline for hepatocellular carcinoma surveillance. Journal of the Korean Medical Association, 2015, 58, 385.	0.3	14
173	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. PLoS ONE, 2015, 10, e0133935.	2.5	36
174	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. Gastroenterology Research and Practice, 2015, 2015, 1-6.	1.5	4
175	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World Journal of Gastroenterology, 2015, 21, 6287.	3.3	51
176	Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease. Medicine (United States), 2015, 94, e573.	1.0	25
177	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 1383-1391.e6.	1.3	371
178	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2037-2045.	2.5	16
179	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo(â^'/â^') mice. European Journal of Pharmacology, 2015, 762, 247-255.	3.5	16
180	Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a Korean population. Infection, Genetics and Evolution, 2015, 33, 72-76.	2.3	36

#	Article	IF	CITATIONS
181	A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. British Journal of Cancer, 2015, 113, 1666-1676.	6.4	73
182	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharmaceutica Sinica B, 2015, 5, 544-553.	12.0	36
183	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 696-705.	2.8	13
184	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. Journal of Medical Virology, 2015, 87, 575-582.	5.0	14
185	Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors. CardioVascular and Interventional Radiology, 2015, 38, 937-945.	2.0	7
186	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. Journal of Hepatology, 2015, 63, 320-328.	3.7	170
187	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World Journal of Hepatology, 2015, 7, 1553.	2.0	37
188	Drs. Lee et al respond:. Journal of Vascular and Interventional Radiology, 2015, 26, 1250-1251.	0.5	0
189	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. Journal of Hepatology, 2015, 63, 1086-1092.	3.7	49
190	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 651-659.	0.5	32
191	Reduction of Oxidative Stress Attenuates Lipoapoptosis Exacerbated by Hypoxia in Human Hepatocytes. International Journal of Molecular Sciences, 2015, 16, 3323-3334.	4.1	6
192	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: Risk of HCC recurrence after radiofrequency ablation. Journal of Hepatology, 2015, 62, 1122-1130.	3.7	70
193	Prominent protein <scp>Z</scp> â€induced thrombin inhibition in cirrhosis: A new functional assay for hypercoagulability assessment. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 784-793.	2.8	1
194	Association between information provision and decisional conflict in cancer patients. Annals of Oncology, 2015, 26, 1974-1980.	1.2	21
195	<scp>CLIF</scp> â€ <scp>SOFA</scp> scoring system accurately predicts shortâ€ŧerm mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. Liver International, 2015, 35, 46-57.	3.9	55
196	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. Antimicrobial Agents and Chemotherapy, 2015, 59, 972-978.	3.2	20
197	Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver International, 2015, 35, 944-952.	3.9	49
198	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. PLoS ONE, 2015, 10, e0130392.	2.5	8

#	Article	IF	CITATIONS
199	Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes. Clinical and Molecular Hepatology, 2015, 21, 150.	8.9	18
200	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clinical and Molecular Hepatology, 2015, 21, 358.	8.9	12
201	Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma. Radiation Oncology Journal, 2015, 33, 36.	1.5	4
202	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. PLoS ONE, 2014, 9, e100870.	2.5	18
203	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. PLoS ONE, 2014, 9, e105679.	2.5	43
204	Association of Polymorphism in MicroRNA 604 with Susceptibility to Persistent Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma. Journal of Korean Medical Science, 2014, 29, 1523.	2.5	17
205	Does antiviral therapy reduce complications of cirrhosis?. World Journal of Gastroenterology, 2014, 20, 7306.	3.3	16
206	Prognostic stratification of brain metastases from hepatocellular carcinoma. Journal of Neuro-Oncology, 2014, 120, 209-214.	2.9	12
207	Telbivudine protects renal function in patients with chronic hepatitis <scp>B</scp> infection in conjunction with adefovirâ€based combination therapy. Journal of Viral Hepatitis, 2014, 21, 873-881.	2.0	24
208	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology, 2014, 271, 909-918.	7.3	97
209	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocrine-Related Cancer, 2014, 21, 343-353.	3.1	20
210	MicroRNAâ€196Aâ€2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. Journal of Medical Virology, 2014, 86, 446-453.	5.0	19
211	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. Journal of Clinical Gastroenterology, 2014, 48, 444-449.	2.2	20
212	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 1730-1737.	3.2	28
213	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. Journal of Cancer Research and Clinical Oncology, 2014, 140, 133-144.	2.5	12
214	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 259-264.	2.9	78
215	Association of a micro <scp>RNA</scp> â€323b polymorphism with the persistence of hepatitis <scp>B</scp> virus infection by the enhancement of viral replication. Journal of Viral Hepatitis, 2014, 21, 853-859.	2.0	17
216	Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. European Journal of Cancer, 2014, 50, 341-350.	2.8	36

#	Article	IF	CITATIONS
217	Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 775-781.	2.8	59
218	Side population in <scp>LX2</scp> cells decreased by transforming growth factorâ€Î². Hepatology Research, 2014, 44, 229-237.	3.4	4
219	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 6710-6716.	3.2	32
220	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine–Choline-Deficient Diet. Digestive Diseases and Sciences, 2014, 59, 1461-1474.	2.3	37
221	Relationship between polymorphisms near the <i><scp>IL</scp>28B</i> gene and spontaneous <scp>HB</scp> sAg seroclearance: a systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2014, 21, 163-170.	2.0	16
222	Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis. Radiology, 2014, 270, 900-909.	7.3	256
223	Occult hepatitis B virus infection. World Journal of Hepatology, 2014, 6, 860.	2.0	81
224	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. PLoS ONE, 2014, 9, e90862.	2.5	11
225	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. PLoS ONE, 2014, 9, e113926.	2.5	17
226	Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. Clinical and Molecular Hepatology, 2014, 20, 18.	8.9	22
227	Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 12039.	3.3	50
228	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. Korean Journal of Internal Medicine, 2014, 29, 580.	1.7	16
229	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology, 2013, 139, 635-643.	2.5	32
230	Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. Journal of Gastroenterology, 2013, 48, 1401-1410.	5.1	35
231	Excellent Outcome in 238 Consecutive Living Donor Liver Transplantations Using the Right Liver Graft in a Large Volume Single Center. World Journal of Surgery, 2013, 37, 1419-1429.	1.6	21
232	Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein. Journal of Vascular and Interventional Radiology, 2013, 24, 274-283.	0.5	42
233	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Digestive Diseases and Sciences, 2013, 58, 1363-1370.	2.3	6
234	Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in <scp>K</scp> orea: A nationwide, multicenter study. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 128-134.	2.8	31

#	Article	IF	CITATIONS
235	The Effect of Pretransplantation Lamivudine Resistance on the Prognosis of Liver Transplant Recipients. Transplantation Proceedings, 2013, 45, 231-235.	0.6	0
236	Lentiviral vector–based insertional mutagenesis identifies genes associated with liver cancer. Nature Methods, 2013, 10, 155-161.	19.0	86
237	Ventriculo-vascular coupling index in asymptomatic mild to moderate aortic stenosis: an important prognostic indicator. European Heart Journal, 2013, 34, P4725-P4725.	2.2	0
238	Small- and Medium-sized Hepatocellular Carcinomas: Monopolar Radiofrequency Ablation with a Multiple-Electrode Switching System—Mid-term Results. Radiology, 2013, 268, 589-600.	7.3	51
239	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. Radiology, 2013, 267, 638-647.	7.3	28
240	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. Human Molecular Genetics, 2013, 22, 4233-4238.	2.9	105
241	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. Clinical Cancer Research, 2013, 19, 4218-4227.	7.0	28
242	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 6325-6332.	3.2	13
243	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1859-1868.	2.8	15
244	Polymorphisms nearInterleukin 28BGene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. Intervirology, 2013, 56, 84-90.	2.8	27
245	Association of polymorphism in MicroRNA 219†with clearance of hepatitis B virus infection. Journal of Medical Virology, 2013, 85, 808-814.	5.0	22
246	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis Bâ€related hepatocellular carcinoma following radiofrequency ablation. Liver International, 2013, 33, 884-893.	3.9	19
247	Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. Scandinavian Journal of Gastroenterology, 2012, 47, 1048-1055.	1.5	19
248	Clinical Prediction of Failure of Lamivudine Prophylaxis for Hepatitis B Virus-Infected Patients Undergoing Cytotoxic Chemotherapy for Malignancy. Antimicrobial Agents and Chemotherapy, 2012, 56, 5511-5519.	3.2	15
249	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2012, 46, 243-250.	2.2	4
250	Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. Journal of Hepatology, 2012, 57, 150-156.	3.7	234
251	Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology, 2012, 56, 1792-1803.	7.3	203
252	Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Digestive and Liver Disease, 2012, 44, 849-854.	0.9	37

#	Article	IF	CITATIONS
253	Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2012, 18, 383.	8.9	96
254	Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology, 2012, 55, 1443-1452.	7.3	110
255	Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology, 2012, 56, 605-613.	7.3	259
256	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. Journal of Bioenergetics and Biomembranes, 2012, 44, 101-115.	2.3	39
257	Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. Abdominal Imaging, 2012, 37, 439-446.	2.0	19
258	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudineâ€resistant hepatitis B virus with or without adefovir resistance. Journal of Medical Virology, 2012, 84, 424-430.	5.0	16
259	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. Digestive Diseases and Sciences, 2012, 57, 813-819.	2.3	31
260	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. PLoS ONE, 2012, 7, e41983.	2.5	23
261	<i>TGFBR3</i> Polymorphisms and Its Haplotypes Associated with Chronic Hepatitis B Virus Infection and Age of Hepatocellular Carcinoma Occurrence. Digestive Diseases, 2011, 29, 278-283.	1.9	11
262	Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virusâ€related hepatocellular carcinoma after ablation therapy. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1638-1645.	2.8	17
263	Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Digestive Diseases and Sciences, 2011, 56, 2130-2136.	2.3	31
264	Genetic Analysis of Complement Component 9 (C9) Polymorphisms with Clearance of Hepatitis B Virus Infection. Digestive Diseases and Sciences, 2011, 56, 2735-2741.	2.3	3
265	No association of TF gene polymorphisms with hepatitis B virus Clearance and hepatocellular carcinoma occurrence in a Korean population. Genes and Genomics, 2011, 33, 209-215.	1.4	0
266	Lack of association between FOS polymorphisms and clearance of HBV infection as well as HCC occurrence. Genes and Genomics, 2011, 33, 327-333.	1.4	0
267	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer, 2011, 11, 435.	2.6	22
268	Lack of association of <i>RAD51</i> genetic variations with hepatitis B virus clearance and occurrence of hepatocellular carcinoma in a Korean population. Journal of Medical Virology, 2011, 83, 1892-1899.	5.0	11
269	Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology, 2011, 258, 627-634.	7.3	264
270	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacologica Sinica, 2011, 32, 912-920.	6.1	35

#	Article	IF	CITATIONS
271	Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-Endemic Area. Digestion, 2011, 84, 17-22.	2.3	57
272	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. Digestion, 2011, 84, 23-28.	2.3	13
273	High Viremia, Prolonged Lamivudine Therapy and Recurrent Hepatocellular Carcinoma Predict Posttransplant Hepatitis B Recurrence. American Journal of Transplantation, 2010, 10, 1658-1668.	4.7	49
274	Absence of Symptom and Intact Liver Function Are Positive Prognosticators for Patients Undergoing Radiotherapy for Lymph Node Metastasis From Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 729-734.	0.8	18
275	Caudate Lobe Hepatocellular Carcinoma Treated with Selective Chemoembolization. Radiology, 2010, 257, 278-287.	7.3	32
276	CCND2 polymorphisms associated with clearance of HBV Infection. Journal of Human Genetics, 2010, 55, 416-420.	2.3	17
277	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Letters, 2010, 298, 9-15.	7.2	49
278	Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 21-26.	2.9	18
279	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 497-507.	2.3	28
280	Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virusâ€related chronic liver disease patients. Journal of Viral Hepatitis, 2009, 16, 444-452.	2.0	21
281	Putative association of transforming growth factor-α polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis, 2009, 17, 518-26.	2.0	18
282	Putative association of DNA methyltransferase 1 (DNMT1) polymorphisms with clearance of HBV infection. BMB Reports, 2009, 42, 834-839.	2.4	13
283	Esophageal Varices in Patients with Cirrhosis: Multidetector CT Esophagography—Comparison with Endoscopy. Radiology, 2007, 242, 759-768.	7.3	98
284	SPP1 polymorphisms associated with HBV clearance and HCC occurrence. International Journal of Epidemiology, 2007, 36, 1001-1008.	1.9	57
285	Putative Association of <i>Fas</i> and <i>FasL</i> Gene Polymorphisms with Clinical Outcomes of Hepatitis B Virus Infection. Intervirology, 2007, 50, 369-376.	2.8	29
286	HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochemical and Biophysical Research Communications, 2007, 363, 776-781.	2.1	35
287	Evaluation of hernia repair operation in Child?Turcotte?Pugh class C cirrhosis and refractory ascites. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 377-382.	2.8	31
288	IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2006, 346, 38-44.	2.1	26

#	Article	IF	CITATIONS
289	Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Experimental and Molecular Medicine, 2006, 38, 694-702.	7.7	46
290	Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepato-Gastroenterology, 2006, 53, 266-70.	0.5	16
291	Identification of variants inNFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients. Human Mutation, 2003, 21, 652-653.	2.5	18
292	Association of TNF-Â promoter polymorphisms with the clearance of hepatitis B virus infection. Human Molecular Genetics, 2003, 12, 2541-2546.	2.9	132
293	Association of transforming growth factor-β1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Experimental and Molecular Medicine, 2003, 35, 196-202.	7.7	74
294	Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Human Molecular Genetics, 2003, 12, 901-906.	2.9	133
295	Modified Lecompte procedure for the anomalies of ventriculoarterial connection. Annals of Thoracic Surgery, 2001, 72, 176-180.	1.3	15
296	Lecompte procedure for complete transposition of the great arteries with ventricular septal defect and pulmonary stenosis. Annals of Thoracic Surgery, 1994, 57, 876-879.	1.3	12